Indrayani Biotech Ltd
Incorporated in 1992, Indrayani Biotech
Ltd is in the business of Foods & Hospitality, Engineering and Healthcare[1]
- Market Cap ₹ 70.5 Cr.
- Current Price ₹ 15.5
- High / Low ₹ 60.5 / 13.0
- Stock P/E
- Book Value ₹ 15.9
- Dividend Yield 0.00 %
- ROCE 2.82 %
- ROE -6.47 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.97 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 33.3%
- Company has a low return on equity of 6.77% over last 3 years.
- Earnings include an other income of Rs.3.13 Cr.
- Company has high debtors of 164 days.
- Promoter holding has decreased over last 3 years: -15.5%
- Working capital days have increased from 238 days to 412 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
0 | 39 | 58 | 50 | 21 | 61 | 163 | 165 | 130 | |
0 | 39 | 57 | 47 | 26 | 54 | 145 | 142 | 124 | |
Operating Profit | -0 | 1 | 1 | 3 | -5 | 7 | 17 | 24 | 6 |
OPM % | -105% | 2% | 1% | 6% | -24% | 11% | 11% | 14% | 5% |
0 | 0 | 0 | 0 | -4 | 0 | 4 | 1 | 3 | |
Interest | 0 | 0 | 0 | 1 | 2 | 2 | 6 | 10 | 12 |
Depreciation | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 4 | 3 |
Profit before tax | -0 | 0 | 0 | 1 | -11 | 4 | 12 | 11 | -6 |
Tax % | 0% | 150% | 300% | 0% | 0% | 0% | 3% | 5% | 6% |
-0 | -0 | -0 | 1 | -11 | 4 | 12 | 10 | -6 | |
EPS in Rs | -0.14 | -0.16 | 2.22 | -3.28 | 1.30 | 2.55 | 1.40 | -0.99 | |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 29% |
TTM: | -21% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -171% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | -24% |
1 Year: | -73% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | 7% |
Last Year: | -6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 4 | 4 | 4 | 34 | 34 | 34 | 46 | 46 |
Reserves | -6 | -0 | -0 | 27 | -15 | -10 | 12 | 22 | 27 |
0 | 0 | 0 | 14 | 16 | 19 | 79 | 113 | 137 | |
1 | 6 | 9 | 7 | 5 | 8 | 31 | 54 | 59 | |
Total Liabilities | 1 | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 268 |
1 | 6 | 6 | 17 | 15 | 17 | 57 | 62 | 58 | |
CWIP | -0 | 0 | 0 | 14 | 14 | 13 | 14 | 20 | 26 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
0 | 4 | 7 | 21 | 11 | 22 | 85 | 151 | 185 | |
Total Assets | 1 | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 268 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
1 | 2 | 6 | 0 | 4 | 16 | -30 | -7 | ||
-3 | -0 | -4 | -1 | -1 | -47 | -16 | 25 | ||
2 | -1 | -1 | -0 | -3 | 33 | 44 | -18 | ||
Net Cash Flow | 0 | 1 | 1 | -1 | 1 | 2 | -2 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 0 | 26 | 26 | 52 | 84 | 84 | 67 | 87 | 164 |
Inventory Days | 365 | 57 | 25 | 14 | 44 | 159 | 182 | ||
Days Payable | 365 | 70 | 77 | 52 | 81 | 141 | 104 | ||
Cash Conversion Cycle | 0 | 26 | 26 | 38 | 32 | 46 | 30 | 106 | 243 |
Working Capital Days | -1,883 | -1 | -8 | 80 | 71 | 56 | 83 | 219 | 412 |
ROCE % | 28% | 12% | -13% | 16% | 23% | 14% | 3% |
Documents
Announcements
- Closure of Trading Window 26 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Jun - Copy of the Newspaper publication pertaining to the Audited FInancial Results (Standaole and Consolidated) for the Quarter and year ended 31st March 2025
- Audited Consolidated Financial Results For The Quarter And Year Ended 31St March 2025 Along With Report Of Statutory Auditors. 13 Jun
-
Outcome Of The Board Meeting Held On 13Th June 2025
13 Jun - Indrayani Biotech reports FY25 consolidated loss of Rs 610.75L vs profit Rs 1,042.25L; revenue Rs 13,022.84L.
- Audited Standalone Results For The Quarter And Year Ended 31St March 2025 12 Jun
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
IBL has multiple business units managed by an
independent team of field experts. It operates
in Food and Hospitality, Dairy, Healthcare & Pharma, Engineering, Biotech, Agriculture and Infrastructure